Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia

Table 1

Laboratory evaluation prior to and during treatment.

	Initial	1st month	2nd month	3rd month	6 months after treatment
HCV-RNA, IU/mL	137.204		Nondetectable		Nondetectable
Genotype	4
Ht, %	23.6	23.2	24.6	25.4	26
Total bilirubin, mg/dL	2.3	4.74	7.76	7.78	2.76
Direct bilirubin, mg/dL	1.2	3.51	3.54	3.6	0.9
ALT, U/L	66	33	38	36	36
Alkaline phosphatase, U/L	115	143	125	143	120
Albumin, g/dL	3.8	3.7	3.8	3.7	3.8
International Normalized Ratio (INR)	1.1	1.1	1.1	1.1	1.1